Hsp90 inhibition sensitizes DLBCL cells to cisplatin
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-022-04407-5
Abstract: Platinum-containing therapy is standard treatment for relapsed Diffuse Large B-Cell Lymphoma (DLBCL). However, the efficacy of treatment is limited by drug resistance leading to relapse. Cisplatin resistance has been linked to impairments of the DNA… read more here.
Keywords: dlbcl cells; hsp90; combination; cells cisplatin ... See more keywords
Abstract 1886: A novel inhibitor of eIF4F protein translation complex sensitizes DLBCL cells to BCL-2 targeted therapy
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-1886
Abstract: The purpose of this project is to investigate the feasibility of using small molecules targeting cap-dependent translation to sensitize B cell lymphoma cells to killing by BCL-2 inhibitors (venetoclax/ ABT-199). We hypothesized that diffuse large… read more here.
Keywords: inhibitor; sbi 756; dlbcl cells; treatment ... See more keywords
Cullin4B Induces Autophagy Participating the Tumorigenesis of Diffuse Large B-Cell Lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.2541.2541
Abstract: Background: Cullin 4B(CUL4B) is a member of cullin family, which is a scaffold protein of Cullin-Ring ligase complexes. CUL4B has been reported to be overexpressed in many solid cancers. And evidence supporting the oncogenic role… read more here.
Keywords: tumorigenesis; dlbcl; dlbcl cells; cell ... See more keywords
Transcriptomics-Based Investigation of Molecular Mechanisms Underlying Apoptosis Induced by ZnO Nanoparticles in Human Diffuse Large B-Cell Lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Nanomedicine"
DOI: 10.2147/ijn.s355408
Abstract: Introduction Zinc oxide nanoparticles (ZnO NPs) show anti-cancer activity. Diffuse Large B-cell Lymphoma (DLBCL) is a type of B-cell malignancies with unsatisfying treatment outcomes. This study was set to assess the potential of ZnO NPs… read more here.
Keywords: cell; apoptosis; molecular mechanisms; zno nps ... See more keywords
CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Cell and Developmental Biology"
DOI: 10.3389/fcell.2021.698503
Abstract: CD30, a member of the TNF receptor superfamily, is selectively expressed on a subset of activated lymphocytes and on malignant cells of certain lymphomas, such as classical Hodgkin Lymphoma (cHL), where it activates critical bystander… read more here.
Keywords: cd30; dlbcl; dlbcl cells; drug conjugate ... See more keywords
Geniposide inhibits proliferation and induces apoptosis of diffuse large B-cell lymphoma cells by inactivating the HCP5/miR-27b-3p/MET axis
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Medical Sciences"
DOI: 10.7150/ijms.51329
Abstract: Diffuse large B-cell lymphoma (DLBCL) is commonly treated with R-CHOP, but ~30 to 50% of the patients are poorly responsive to this strategy. Geniposide, an extract from the Gardenia jasminoides Ellis, plays antitumor roles in… read more here.
Keywords: hcp5; dlbcl; apoptosis; dlbcl cells ... See more keywords